It has been reported that a risk sharing agreement (RSA) has been renewed for the second time for Stivarga (regorafenib; Bayer Korea), a second-line treatment for liver cancer.

The news comes two months before the reimbursable RSA contract for Stivarga is set to expire on May 31st.

According to industry sources on the 18th, the National Health Insurance Service (NHIS) agreed to renew a RSA with Bayer for Stivarga. Under the RSA, Stivarga is expected to receive reimbursement for five years until May 2029.

Stivarga was first listed In June 2016 as reimbursable under RSA for the first time for treating gastrointestinal stromal tumor (GIST).

Then, since May 20